Preventing rabies with the Verorab® vaccine: 1985-2005. Twenty years of clinical experience

Travel Medicine and Infectious Disease

Volumn 5, Issue 6, 2007, Pages 327-348

  Toovey, Stephen ^a  

^a NONE   (Switzerland)

Author keywords

Post exposure treatment; Pre exposure; Prophylaxis; Rabies; Rabies vaccine; Vero cell; Verorab

Indexed keywords

ANTIBIOTIC AGENT; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPLOID CELL VACCINE; ESSEN; NEUTRALIZING ANTIBODY; PLACEBO; PROPIOLACTONE; RABIES IMMUNOGLOBULIN; RABIES VACCINE; TETANUS TOXOID; THAI RED CROSS INTRADERMAL; UNCLASSIFIED DRUG; ZAGREB;

ACTIVE IMMUNIZATION; ANGIONEUROTIC EDEMA; ANTIBODY TITER; ARTICLE; CHILD CARE; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INJECTION SITE INDURATION; INJECTION SITE PAIN; LYMPHADENOPATHY; PAIN; PREGNANCY; PRIORITY JOURNAL; PRURITUS; RABIES; REPEATED DRUG DOSE; SERUM SICKNESS; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; URTICARIA;

ADOLESCENT; AGED; ANIMALS; CERCOPITHECUS AETHIOPS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION ROUTES; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; PREGNANCY; RABIES; RABIES VACCINES; VERO CELLS;

EID: 35548936460     PISSN: 14778939     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tmaid.2007.07.004     Document Type: Article

References (79)

1. Chutivongse S., Wilde H., Benjavongkulchai M., Chomchey P., and Punthawong S. Postexposure rabies vaccination during pregnancy: effect on 202 women and their infants. Clin Infect Dis 20 4 (1995) 818-820
2. Barme M., and Tsiang H. Human antirabies vaccine from pasteur to the present. Bull Acad Nat Med 179 5 (1995) 1023-1032
3. Rupprecht C.E., Hanlon C.A., and Hemachudha T. Rabies re-examined. Lancet Infect Dis 2 6 (2002) 327-343
4. Ajjan N., and Pilet C. Comparative study of the safety and protective value, in pre-exposure use, of rabies vaccine cultivated on human diploid cells (HDCV) and of the new vaccine grown on Vero cells. Vaccine 7 2 (1989) 125-128
5. Svjetlicic M., Vodopija I., Smerdel S., Ljubicic M., Baklaic Z., Vincent-Falquet J.C., et al. Compatibility and immunogenicity of Merieux's purified vero rabies vaccine (PVRV) in healthy subjects. In: Vodopija I., Nicholson K.G., Smerdel S., and Bijok U. (Eds). Improvements in rabies post-exposure treatment (1985), Institute of Public Health, Zagreb 123-127
6. Fournier P., Montagnon B.J., Vincent-Falquet J.C., Ajjan N., Drucker J., and Roumiantzeff M. A new vaccine produced from Rabies virus cultivated on Vero cell. In: Vodopija I., Nicholson K.G., Smerdel S., and Bijok U. (Eds). Improvements in rabies post-exposure treatment. 1st ed (1985), Institute of Public Health, Zagreb 115-121
7. Suntharasamai P., Warrell M.J., Warrell D.A., Viravan C., Looareesuwan S., Supanaranond W., et al. New purified Vero-cell vaccine prevents rabies in patients bitten by rabid animals. Lancet 2 8499 (1986) 129-131
8. Warrell M.J., and Warrell D.A. Rabies and other lyssavirus diseases. Lancet 363 9413 (2004) 959-969
9. Hattwick M.A.W. Human rabies. Public Health Rev 3 3 (1974) 229-274
10. Hattwick M.A., Weis T.T., Stechschulte C.J., Baer G.M., and Gregg M.B. Recovery from rabies. A case report. Ann Intern Med 76 6 (1972) 931-942
11. Jackson A.C., Warrell M.J., Rupprecht C.E., Ertl H.C., Dietzschold B., O'Reilly M., et al. Management of rabies in humans. Clin Infect Dis 36 1 (2003) 60-63
12. Willoughby Jr. R.E., Tieves K.S., Hoffman G.M., Ghanayem N.S., mile-Lefond C.M., Schwabe M.J., et al. Survival after treatment of rabies with induction of coma. N Engl J Med 352 24 (2005) 2508-2514
13. WHO Expert Committee on Rabies. World Health Organ Tech Rep Ser 824 (1992) 1-84
14. Favi M., Yung V., Roos O., Rodriguez L., Trujillo R., and Acevedo A. Immune response of suckling mouse brain (CRL) rabies vaccine and tissue culture rabies vaccine (Verorab) in pre-exposure prophylaxis in humans. Rev Med Chile 132 1 (2004) 41-46
15. Plotkin S.A. Rabies. Clin Infect Dis 30 1 (2000) 4-12
16. Chanthavanich P., Suntharasamai P., Warrell M.J., Viravan C., Looareesuwan S., Supanaranond W., et al. Antibody response to suckling mouse brain rabies vaccines for post exposure treatment. Trans R Soc Trop Med Hyg 81 2 (1987) 260-263
17. Khawplod P., Wilde H., Yenmuang W., Benjavongkulchai M., and Chomchey P. Immune response to tissue culture rabies vaccine in subjects who had previous postexposure treatment with Semple or suckling mouse brain vaccine. Vaccine 14 16 (1996) 1549-1552
18. Parviz S., Luby S., and Wilde H. Postexposure treatment of rabies in Pakistan. Clin Infect Dis 27 4 (1998) 751-756
19. Swamy H.S., Anisya V., Nandi S.S., and Kaliaperumal V.G. Neurological complications due to Semple-type antirabies vaccine. Clinical and therapeutic aspects. J Assoc Physicians India 39 9 (1991) 667-669
20. Piyasirisilp S., and Hemachudha T. Neurological adverse events associated with vaccination. Curr Opin Neurol 15 3 (2002) 333-338
21. Hemachudha T., Griffin D.E., Giffels J.J., Johnson R.T., Moser A.B., and Phanuphak P. Myelin basic protein as an encephalitogen in encephalomyelitis and polyneuritis following rabies vaccination. N Engl J Med 316 7 (1987) 369-374
22. Hemachudha T., Griffin D.E., Johnson R.T., and Giffels J.J. Immunological studies of patients with chronic encephalitis induced by post-exposure Semple Rabies vaccine. Neurology 38 1 (1988) 42-44
23. Chaleomchan W., Hemachudha T., Sakulramrung R., and Deesomchok U. Anticardiolipin antibodies in patients with rabies vaccination induced neurological complications and other neurological diseases. J Neurol Sci 96 2-3 (1990) 143-151
24. Swaddiwuthipong W., Weniger B.G., Wattanasri S., and Warrell M.J. A high rate of neurological complications following Semple anti-rabies vaccine. Trans R Soc Trop Med Hyg 82 3 (1988) 472-475
25. Swaddiwudhipong W., Prayoonwiwat N., Kunasol P., and Choomkasien P. A high incidence of neurological complications following Semple anti-rabies vaccine. Southeast Asian J Trop Med Public Health 18 4 (1987) 526-531
26. Bahri F., Letaief A., Ernez M., Elouni J., Chekir T., BenAmmou S., et al. Neurological complications in adults given post-exposure Semple-type rabies vaccine. Press Med 25 10 (1996) 491-493
27. WHO Expert Consultation on Rabies. First report 931, WHO technical report series 13-7-2005. Geneva, Switzerland: WHO; 2005. p. 1-121.
28. Knobel D.L., Cleaveland S., Coleman P.G., Fevre E.M., Meltzer M.I., Miranda M.E., et al. Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ 83 5 (2005) 360-368
29. Goswami A., Plun-Favreau J., Nicoloyannis N., Sampath G., Siddiqui M.N., and Zinsou J.A. The real cost of rabies post-exposure treatments. Vaccine 23 23 (2005) 2970-2976
30. WHO Expert Committee on Rabies. Seventh report 709. WHO technical report series. Geneva, Switzerland: WHO; 1984.
31. Meslin F.X. Rabies as a traveller's risk, especially in high-endemicity areas. J Travel Med 12 Suppl (2005) 30-40
32. Thongcharoen P., Wasi C., Sirikawin S., Chaiprasithikul P., and Puthavathana P. Rabies and post-exposure prophylaxis in Thai children. Asian Pac J Allergy Immunol 7 1 (1989) 41-46
33. Sriaroon C., Jaijaroensup W., Tantawichien T., Benjawongkunchai M., Supich C., and Wilde H. Common dilemmas in managing rabies exposed subjects. Travel Med Infect Dis 3 1 (2005) 1-7
34. Suntharasamai P., Chantavanich P., Warrell M.J., Looareesuwan S., Karbwang J., Supanaranond W., et al. Purified Vero cell rabies vaccine and human diploid cell strain vaccine: comparison of neutralizing antibody responses to post-exposure regimens. J Camb Hyg 96 (1986) 483-489
35. Wilde H., Tipkong P., and Khawplod P. Economic issues in postexposure rabies treatment. J Travel Med 6 4 (1999) 238-242
36. Lang J., Duong G.H., Nguyen V.G., Le T.T., Nguyen C.V., Kesmedjian V., et al. Randomised feasibility trial of pre-exposure rabies vaccination with DTP-IPV in infants. Lancet 349 9066 (1997) 1663-1665
37. Lang J., Hoa D.Q., Gioi N.V., Vien N.C., Nguyen C.V., Rouyrre N., et al. Immunogenicity and safety of low-dose intradermal rabies vaccination given during an Expanded Programme on immunization session in Viet Nam: results of a comparative randomized trial. Trans R Soc Trop Med Hyg 93 2 (1999) 208-213
38. Dureux B., Canton P., Gerard A., Strady A., Deville J., Lienard M., et al. Rabies vaccine for human use, cultivated on Vero cells. Lancet 2 8498 (1986) 98
39. Vodopija I., Sureau P., Lafon M., Baklaic Z., Ljubicic M., Svjetlicic M., et al. An evaluation of second generation tissue culture rabies vaccines for use in man: a four-vaccine comparative immunogenicity study using a pre-exposure vaccination schedule and an abbreviated 2-1-1 postexposure schedule. Vaccine 4 4 (1986) 245-248
40. Sabchareon A., Chantavanich P., Pasuralertsakul S., Pojjaroen-Anant C., Prarinyanupharb V., Attanath P., et al. Persistence of antibodies in children after intradermal or intramuscular administration of preexposure primary and booster immunizations with purified Vero cell rabies vaccine. Pediatr Infect Dis J 17 11 (1998) 1001-1007
41. Kitala P.M., Lindqvist K.J., Koimett E., Johnson B.K., Chunge C.N., Perrin P., et al. Comparison of human immune responses to purified Vero cell and human diploid cell rabies vaccines by using two different antibody titration methods. J Clin Microbiol 28 8 (1990) 1847-1850
42. Hacibektasoglu A., Inal A., Eyigun C., Barut A., and Turkay F.A. Comparison of PVRV and HDCV rabies vaccines as to immunity, reliability and protective value. Mikrobiyol Bul 26 1 (1992) 26-36
43. Strady A., Lang J., Lienard M., Blondeau C., Jaussaud R., and Plotkin S.A. Antibody persistence following preexposure regimens of cell-culture rabies vaccines: 10-year follow-up and proposal for a new booster policy. J Infect Dis 177 5 (1998) 1290-1295
44. Suntharasamai P., Chanthavanich P., Supanaranond W., and Warrell M.J. One year booster vaccination with purified vero cell rabies vaccine. Trans R Soc Trop Med Hyg 82 4 (1988) 633
45. Suntharasamai P., Warrell M.J., Warrell D.A., Chanthavanich P., Looareesuwan S., Supapochana A., et al. Early antibody responses to rabies post-exposure vaccine regimens. Am J Trop Med Hyg 36 1 (1987) 160-165
46. Chadli A., Merieux C., Arrouji A., and Ajjan N. Study of the efficacy of a vaccine produced from rabies virus cultivated on Vero cell. In: Vodopija I., Nicholson K.G., Smerdel S., and Bijok U. (Eds). Improvements in rabies post-exposure treatment. Ist ed (1985), Institute of Public Health, Zagreb 129-136
47. Jaiiaroensup W., Lang J., Thipkong P., Wimalaratne O., Samranwataya P., Saikasem A., et al. Safety and efficacy of purified Vero cell rabies vaccine given intramuscularly and intradermally. (Results of a prospective randomized trial). Vaccine 16 16 (1998) 1559-1562
48. Wang X.J., Lang J., Tao X.R., Shu J.D., Le M.V., Wood S.C., et al. Immunogenicity and safety of purified Vero-cell rabies vaccine in severely rabies-exposed patients in China. Southeast Asian J Trop Med Public Health 31 2 (2000) 287-294
49. Lang J., Attanath P., Quiambao B., Singhasivanon V., Chanthavanich P., Montalban C., et al. Evaluation of the safety, immunogenicity, and pharmacokinetic profile of a new, highly purified, heat-treated equine rabies immunoglobulin, administered either alone or in association with a purified, Vero-cell rabies vaccine. Acta Trop 70 3 (1998) 317-333
50. Seghal S., Bhattacharya D., and Bhardwaj M. Five-year longitudinal study of efficacy and safety of purified Vero cell rabies vaccine for post-exposure prophylaxis of rabies in Indian population. J Commun Dis 29 1 (1997) 23-28
51. Sudarshan M.K., Madhusudana S.N., and Mahendra B.J. Post-exposure prophylaxis with purified vero cell rabies vaccine during pregnancy-safety and immunogenicity. J Commun Dis 31 4 (1999) 229-236
52. Kositprapa C., Limsuwun K., Wilde H., Jaijaroensup W., Saikasem A., Khawplod P., et al. Immune response to simulated postexposure rabies booster vaccinations in volunteers who received preexposure vaccinations. Clin Infect Dis 25 3 (1997) 614-616
53. Vodopija R., Lafont M., Baklaic Z., Ljubicic M., Svjetlicic M., and Vodopija I. Persistence of humoral immunity to rabies 1100 days after immunization and effect of a single booster dose of rabies vaccine. Vaccine 15 5 (1997) 571-574
54. Colnot F., Sureau P., Alexandre J.L., Arnaudo J.P., Hesse J.Y., and Jeanmaire H. Post-exposure antirabies vaccination. Early serological response to vaccine cultivated on VERO cells using a reduced 2-1-1 schedule. Press Med 23 35 (1994) 1609-1612
55. Chutivongse S., Wilde H., Fishbein D.B., Baer G.M., and Hemachudha T. One-year study of the 2-1-1 intramuscular postexposure rabies vaccine regimen in 100 severely exposed Thai patients using rabies immune globulin and Vero cell rabies vaccine. Vaccine 9 8 (1991) 573-576
56. Lang J., Simanjuntak G.H., Soerjosembodo S., and Koesharyono C. Suppressant effect of human or equine rabies immunoglobulins on the immunogenicity of post-exposure rabies vaccination under the 2-1-1 regimen: a field trial in Indonesia. MAS054 Clinical Investigator Group. Bull World Health Organ 76 5 (1998) 491-495
57. Plotkin S.A., Rupprecht C.E., and Koprowski H. Rabies vaccine. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccines. 3rd ed (2004), Saunders, Philadelphia, PA 1011-1038
58. Chutivongse S., Wilde H., Supich C., Baer G.M., and Fishbein D.B. Postexposure prophylaxis for rabies with antiserum and intradermal vaccination. Lancet 335 8694 (1990) 896-898
59. Phanuphak P., Khawplod P., Sirivichayakul S., Siriprasomsub W., Ubol S., and Thaweepathomwat M. Humoral and cell-mediated immune responses to various economical regimens of purified Vero cell rabies vaccine. Asian Pac J Allergy Immunol 5 1 (1987) 33-37
60. Khawplod P., Benjavongkulchai M., Limusanno S., Chareonwai S., Kaewchompoo W., Tantawichien T., et al. Four-site intradermal postexposure boosters in previously rabies vaccinated subjects. J Travel Med 9 3 (2002) 153-155
61. Khawplod P., Wilde H., Tantawichien T., Limusanno S., Mitmoonpitak C., et al. Potency, sterility and immunogenicity of rabies tissue culture vaccine after reconstitution and refrigerated storage for 1 week. Vaccine 20 17-18 (2002) 2240-2242
62. Phanuphak P., Khaoplod P., Benjavongkulchai M., Chutivongse S., and Wilde H. What happens if intradermal injections of rabies vaccine are partially or entirely injected subcutaneously?. Bull World Health Organ 68 1 (1990) 83-85
63. Bernard K.W., Roberts M.A., Sumner J., Winkler W.G., Mallonee J., Baer G.M., et al. Human diploid cell rabies vaccine. Effectiveness of immunization with small intradermal or subcutaneous doses. JAMA 247 8 (1982) 1138-1142
64. Chutivongse S., and Wilde H. Postexposure rabies vaccination during pregnancy: experience with 21 patients. Vaccine 7 6 (1989) 546-548
65. Sudarshan M.K., Madhusudana S.N., Mahendra B.J., Ashwathnarayana D.H., Jayakumary M., and Gangaboriah. Post exposure rabies prophylaxis with Purified Verocell Rabies Vaccine: a study of immunoresponse in pregnant women and their matched controls. Indian J Public Health 43 2 (1999) 76-78
66. Figueroa D.R., Ortiz Ibarra F.J., and Arredondo Garcia J.L. Post-exposure antirabies prophylaxis in pregnant women. Ginecol Obstet Mex 62 (1994) 13-16
67. Chanthavanich P., Sabchareon A., Singhasivanon V., Pojjaroen-Anant C., Chongsuphajaisiddhi T., and Kittikoon P. Dose-related antibody responses to purified Vero cell rabies vaccine in healthy Thai children. In: Dodet B., and Meslin F.X. (Eds). Rabies control in Asia (1997), Elsevier, Paris 97-100
68. Thisyakorn U., Pancharoen C., Ruxrungtham K., Ubolyam S., Khawplod P., Tantawichien T., et al. Safety and immunogenicity of preexposure rabies vaccination in children infected with human immunodeficiency virus type 1. Clin Infect Dis 30 1 (2000) 218
69. Pancharoen C., Thisyakorn U., Tantawichien T., Jaijaroensup W., Khawplod P., and Wilde H. Failure of pre- and postexposure rabies vaccinations in a child infected with HIV. Scand J Infect Dis 33 5 (2001) 390-391
70. Hemachudha T., Mitrabhakdi E., Wilde H., Vejabhuti A., Siripataravanit S., and Kingnate D. Additional reports of failure to respond to treatment after rabies exposure in Thailand. Clin Infect Dis 28 1 (1999) 143-144
71. Wilde H., Sirikawin S., Sabcharoen A., Kingnate D., Tantawichien T., Harischandra P.A., et al. Failure of postexposure treatment of rabies in children. Clin Infect Dis 22 2 (1996) 228-232
72. Kreindel S., McGuill M., Rupprecht C., and DeMaraia A.J. Rabies post exposure prophylaxis: when is it appropriate?. Infect Dis Clin Practice 7 (1998) 274-279
73. Thongcharoen P., Wasi C., Sirikawin S., Chaiprasithikul P., and Puthavathana P. Rabies and post-exposure prophylaxis in Thai children. Asian Pac J Allergy Immunol 7 1 (1989) 41-46
74. Systemic allergic reactions following immunization with human diploid cell rabies vaccine. Morb Mortal Wkly Rep 1984;33(14):185-7.
75. Deutsch A.J., Dreesen D.W., and Bernard K.W. Serum sickness like reaction associated with skin-sensitizing antibody following booster dose of rabies human-diploid cell vaccine. J Allergy Clin Immunol 75 1 (1985) 108
76. Dreesen D.W., Bernard K.W., Parker R.A., Deutsch A.J., and Brown J. Immune complex-like disease in 23 persons following a booster dose of rabies human diploid cell vaccine. Vaccine 4 1 (1986) 45-49
77. Anderson M.C., Baer H., Frazier D.J., and Quinnan G.V. The role of specific IgE and beta-propiolactone in reactions resulting from booster doses of human diploid cell rabies vaccine. J Allergy Clin Immunol 80 6 (1987) 861-868
78. Chutivongse S., Supich C., and Wilde H. Acceptability and efficacy of purified Vero-cell rabies vaccine in Thai children exposed to rabies. Asia Pac J Public Health 2 3 (1988) 179-184
79. [Anon]. Systemic allergic reactions after immunization with human-diploid cell rabies vaccine. Drug IntellClin Pharm 18 7-8 (1984) 675-676